Capecitabine: all 1,069 studies that test it
Page 6 of 11. Open to participants first (152), then studies with results posted, then the rest; newest registration first within each.
- EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Active, not recruitingNCT04072107Phase 2
- The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.Status unknownNCT04065282Phase 2
- Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver MetastasesWithdrawnNCT04037241Phase 2/3
- Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled StudyStatus unknownNCT04012918Phase 2
- Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic AdenocarcinomaTerminatedNCT03974854Phase 2
- Metronomic Chemotherapy With Capecitabine for Pancreatic CancerStatus unknownNCT03959150Phase 2/3
- Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast CancerCompletedNCT03958721Phase 1
- Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast CancerStatus unknownNCT03923166Phase 2
- The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric CancerStatus unknownNCT03889626Phase 3
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCTerminatedNCT03858972Phase 2
- A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaCompletedNCT03852251Phase 1/2
- TNT to Increase the Clinical Complete Response Rate for Distal LARCActive, not recruitingNCT03840239Phase 2
- QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.Active, not recruitingNCT03828227Phase 3
- Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant ChemotherapyStatus unknownNCT03821454Not applicable
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast CancerStatus unknownNCT03775525Phase 1
- Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric CancerActive, not recruitingNCT03764553Phase 2
- Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal CancerStatus unknownNCT03729687Phase 2
- A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerActive, not recruitingNCT03691051Phase 2
- A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCCStatus unknownNCT03678649Phase 2
- Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast CancerStatus unknownNCT03647514Not applicable
- SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerTerminatedNCT03645876Phase 2
- Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant TherapyStatus unknownNCT03638648Phase 2
- Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric CancerStatus unknownNCT03598348Phase 3
- Herzuma-capecitabine/Cisplatin for Gastric CancerStatus unknownNCT03588533Phase 2
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2
- SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCCCompletedNCT03578874Phase 2
- Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRCCompletedNCT03564912Phase 1/2
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnNCT03563170Phase 1/2
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
- Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic CancerActive, not recruitingNCT03523312Phase 2
- Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast CancerCompletedNCT03518242Phase 1
- A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant TherapyCompletedNCT03473639Phase 1
- Association of Capecitabine Pharmacokinetics and Toxicity With AgingStatus unknownNCT03465202Phase 4
- Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)Active, not recruitingNCT03448835Phase 2
- A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed ConditionStatus unknownNCT03435666Phase 1
- Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.CompletedNCT03428529Phase 2/3
- Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedNCT03427359Phase 2
- The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage TherapyStatus unknownNCT03423849Phase 2/3
- Carbon Ion Radiation Therapy for Locally Advanced Pancreatic CancerCompletedNCT03403049Phase 1
- XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Phase 3
- CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomasTerminatedNCT03387592Phase 2
- Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal CancerStatus unknownNCT03381352Phase 2
- Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerCompletedNCT03377387Phase 1/2
- the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line TreatmentTerminatedNCT03358004Phase 2
- Two Chemotherapy Regimens Plus or Minus BevacizumabActive, not recruitingNCT03351296Phase 2
- Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCTerminatedNCT03326674Phase 3
- Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine TumorStatus unknownNCT03279601Phase 2
- Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric CancerActive, not recruitingNCT03257163Phase 2
- Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract CancerCompletedNCT03231176Phase 2
- Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast CancerStatus unknownNCT03204734Phase 2
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal CancerTerminatedNCT03158610Phase 2/3
- Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARCCompletedNCT03156036Phase 2
- Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal CancerTerminatedNCT03153280Phase 1
- Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal CancerCompletedNCT03146377Phase 2
- Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract CancerWithdrawnNCT03129074Phase 2
- Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLMStatus unknownNCT03125161Phase 3
- Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by SurgeryWithdrawnNCT03117855Phase 1
- Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular CarcinomaStatus unknownNCT03114085Phase 2
- Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownNCT03080805Phase 3
- Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.Status unknownNCT03042000Not applicable
- Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal CancerStatus unknownNCT03038217Phase 3
- Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast CancerStatus unknownNCT03011060Phase 3
- PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast CancerStatus unknownNCT03006614Phase 3
- Adjuvant Chemotherapy In Elderly With Colon Cancer Stage IIICompletedNCT02978612Phase 2
- Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02958111Phase 3
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
- Capecitabine and Lenvatinib With External Radiation in Rectal AdenocarcinomaCompletedNCT02935309Phase 1
- Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabCompletedNCT02934529Phase 3
- Multicentric Randomised Trial for Resectable Gastric CancerActive, not recruitingNCT02931890Phase 2
- Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
- Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal CancerTerminatedNCT02910843Phase 1
- Pembrolizumab, Trastuzumab, HER2 Positive Gastric CancerStatus unknownNCT02901301Phase 1/2
- Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerSuspendedNCT02897050Phase 2
- Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRCStatus unknownNCT02893540Phase 2/3
- Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal CancerCompletedNCT02864849Phase 2
- To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast CancerCompletedNCT02846428Phase 2
- Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell CancerTerminatedNCT02842125Phase 1/2
- X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast CancerStatus unknownNCT02838238Phase 2
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02786641Phase 3
- MEK162 in Combination With Capecitabine in Advanced Biliary Tract CancerCompletedNCT02773459Phase 1/2
- Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast CancerCompletedNCT02767661Phase 3
- Study of ONO-4538 in Gastric CancerCompletedNCT02746796Phase 2/3
- 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsTerminatedNCT02736448Phase 2
- Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric CancerTerminatedNCT02720926Phase 1
- Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract CancersWithdrawnNCT02720601Phase 2
- Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT02716766Phase 2
- Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal CancerStatus unknownNCT02688023Phase 2
- Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2